Aurobindo shares move up on USFDA nod for Amoxicillin
Source: IRIS | 17 Sep, 2014, 10.05AM
|
|
|
|
|
| Rating: NAN / 5 stars. |
 Comments | Post Comment |
|
 Aurobindo Pharma, one of the leading drug makers, witnessed a rise in share prices on Wednesday after the company has received new product approval from the US Food & Drug Administration (USFDA). The product approval will allow the company to manufacture and market Amoxicillin for Oral Suspension USP 125mg/5mL and 250mg/5mL (ANDA 204030).
 Amoxicillin for Oral Suspension is the generic equivalent to the reference listed drug product (RLD). Amoxicillin is indicated in the treatment of infections due to susceptible βetalactamase-negative strains of the designated microorganisms.
Shares of the company are trading at Rs 865, up Rs 10.7, or 1.25% at the Bombay Stock Exchange (BSE) on Wednesday at 9:54 a.m.
The scrip has touched an intra-day high of Rs 880 and low of Rs 857.10. The total volume of shares traded at the BSE is 50,891.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
